The Federal Trade Commission says Martin Shkreli used livestreams to trade pharmaceutical stocks and discuss drug companies in violation of a lifetime ban from the industry. The FTC and several states laid out the allegations in a filing describing four phases of activity, from a 2022 trading competition to a challenge launched in June 2026 with a $10 million account.
FTC Commissioner Mark Meador said the record showed Shkreli “chose to blatantly disregard the order after leaving prison.” The filing alleges he traded pharmaceutical stocks and sought to influence pharmaceutical companies through public commentary. It argues that a lifetime ban only works if violations bring consequences proportionate to the order. The filing presents allegations, not a final determination that Shkreli violated the injunction.
Shkreli said he was surprised by the FTC’s filing. In a social media post, he accused New York Attorney General Letitia James of trying to limit free speech and said he had not expected that from “Trump’s FTC.” That is a political response to the filing, rather than a detailed account of the alleged trades.
The FTC’s timeline begins with a 2022 trading competition against another YouTuber. It then describes Shkreli shorting a small biotech company in 2024, along with trading in other pharmaceutical stocks. In 2025, the filing says, he shorted three small biotech firms as part of another trading challenge while trading other pharmaceutical stocks. The latest challenge allegedly began in June 2026 with a $10 million account.
Shorting a stock means betting its price will fall, typically by borrowing shares to sell and hoping to buy them back later at a lower price. Shkreli discussed pharmaceutical companies on livestreams, evaluated stocks and predicted outcomes of pivotal clinical trials, the filing says. In 2025, he described his “magic trick” this way: “It doesn’t matter what trades I make because I can always find a couple of biotech stocks to smoke.”
Later that year, he advised viewers to short a pharmaceutical company’s stock. The company’s share price quickly fell 17 percent, according to the filing. That sequence does not, by itself, establish that his comments caused the decline. But it illustrates why public commentary from someone trading the stocks he discusses can attract regulatory scrutiny: an audience may treat the livestream as entertainment, analysis or a cue to trade, while the speaker may have a financial position of his own.
The filing says Shkreli sometimes displayed trading accounts on screen and that FTC staff reviewed only a fraction of his social media activity. The agency and states argue that the stocks discussed publicly are “likely the tip of the iceberg.” They also cite Shkreli referring to other accounts, including one remark: “I have some other accounts that I’[d] show you, but, like, I know feds are watching, so f[*]ck that.”
Livestreams turn financial commentary into a performance: viewers can watch the confident prediction, the account balance and, sometimes, the reaction when the market moves. But the format does not make an industry ban less binding. The next question is what consequences the FTC and states will seek—and what a court makes of the alleged trades and broadcasts.
Sources: Glitch Please! and Ars Technica — https://arstechnica.com/health/2026/10/martin-shkreli-livestreamed-himself-violating-lifetime-pharma-ban-ftc-says/ — Reporting and source material for the FTC allegations and Shkreli’s response.
Generated by AI
